Drug Patents owned by Eiger Biopharms
1. List of Zokinvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828356 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2023
(6 months from now) | |
| US7838531 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2024
(1 year, 4 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 20, 2027 |
| New Chemical Entity Exclusivity (NCE) | Nov 20, 2025 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 2024-11-20
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE;ORAL
More Information on Dosage
ZOKINVY family patents
16
United States
2
European Union
1
Australia
1
Canada
1
Austria
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic